O-RAN-ALLIANCE-E.V.
16.3.2021 12:30:05 CET | Business Wire | Press release
As of February 23, 2021, the O-RAN ALLIANCE welcomes DISH Network as a new member of its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005553/en/
“Carriers around the world are recognizing the importance of building next-generation, programmable networks that are open, intelligent and flexible, making the work of the O-RAN ALLIANCE more critical than ever,” said Sidd Chenumolu, DISH vice president of technology development. “At DISH, we are in a unique position as we build a 5G network entirely upon O-RAN standards, and the work of this organization creates a unified roadmap as our partners join us in developing a disaggregated and open RAN. We look forward to playing a continued role in the success of the O-RAN ALLIANCE and the development of standards that enhance connectivity worldwide.”
O-RAN ALLIANCE’s Minimum Viable Plan (MVP) Towards Commercial O-RAN Solutions
O-RAN’s specification effort, open software development, as well as testing and integration, will focus on priorities set by its operator members. This approach will allow the O-RAN ecosystem players to prioritize the delivery of a minimum viable set of end-to-end O-RAN solutions applicable in commercial networks.
The first release of the MVP includes already published specifications and additional work items in the area of:
- Open fronthaul specifications provide fully specified control, user and synchronization interface, management plane interface between O-RU and O-DU, and relevant conformance and interoperability tests, enabling multi-vendor interoperability.
- Open transport defines the requirements of xhaul transport, proposes the best practices of deploying WDM and IP technologies in xhaul.
- Open hardware offers hardware reference designs for different modes of indoor picocell, outdoor microcell, outdoor Macrocell and open fronthaul gateway to accelerate the use of whitebox and facilitate RAN ecosystem diversity.
- Open stack provides a software reference design for O-CU/O-DU architecture, interfaces, internal modules, and APIs, to promote and guide the open source software development.
- Open cloud presents O-Cloud reference design with the fundamental synchronization requirements and real life deployment recommendations.
- Testing and integration sets the criteria and guidelines for the formation of Open Testing and Integration Centers (OTICs) , ensuring consistency and quality of the testing of O-RAN products and solutions.
Subsequent O-RAN releases will extend the MVP with additional features and functionalities based on continuing surveys and updates of operators’ deployment priorities.
28 New or Updated O-RAN Specifications Released since November 2020
On February 26, 2021, the O-RAN ALLIANCE published another 28 specification documents, including 10 new titles. For more details on the new specifications, please check this O-RAN blog post . To download O-RAN specifications, please proceed to www.o-ran.org/specifications .
O-RAN Open Summit Held on February 25, 2021 Available for Re-play
The O-RAN Open Summit on February 25, 2021 has gained attention with more than 2500 global visitors. The recording of Open Summit is available at the O-RAN website . The recording includes full content of the event, including five keynotes:
- Opening address - Alex Jinsung Choi , COO of O-RAN ALLIANCE and SVP Technology Strategy & Innovation of Deutsche Telekom
- Chairman address - Andre Fuetsch , Chairman of the O-RAN ALLIANCE and Chief Technology Officer of AT&T
- O-RAN Technical progress - Chih-Lin I , Co-Chair of O-RAN Technical Steering Committee and China Mobile Chief Scientist, Wireless Technologies, China Mobile Research Institute
- Testing and Integration Focus Group update - David Orloff , Co-chair of O-RAN Testing and Integration Focus Group, AT&T
- O-RAN Software Community update - Jack Murray , Co-Chair of OSC Technical Oversight Committee, AT&T
The event recording also includes the panel discussion on ‘Paths to O-RAN implementation ’ providing valuable insights on possible ways towards open RAN introduction in the public mobile networks. The panelists represent a great variety of players in the O-RAN ecosystem: AT&T, NTT DOCOMO, Orange, TIM, O-RAN ALLIANCE, Intel, Keysight, ONF, Nokia and Radisys.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 270 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005553/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom